Digital tools are becoming increasingly important across veterinary medicine, from clinical workflows to client communication and practice operations.

According to the announcement, IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test. The development is relevant because it reflects how animal health companies, service providers, and technology platforms are responding to changing expectations in veterinary care.

What Was Announced

The test measures a well-established biomarker used to evaluate heart disease in companion animals, a condition that affects approximately 1 in 6 cats 1 and 1 in 10 dogs 2, yet remains underassessed in general practice. At the same time, Catalyst proBNP expands access to a global cardiac testing opportunity estimated at approximately $4 billion 3 while giving veterinarians a practical new too…